Helen Louise Collins - 12 Feb 2026 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Ben Hohl, by power of attorney
Issuer symbol
ELVN
Transactions as of
12 Feb 2026
Net transactions value
$0
Form type
4
Filing time
17 Feb 2026, 19:47:55 UTC
Previous filing
06 Jun 2025
Next filing
19 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Collins Helen Louise CHIEF MEDICAL OFFICER C/O ENLIVEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, BOULDER /s/ Ben Hohl, by power of attorney 17 Feb 2026 0001701247

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Award $0 +25,000 $0.000000 25,000 12 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +150,000 $0.000000 150,000 12 Feb 2026 Common Stock 150,000 $27.16 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 1/4th of the RSUs will vest on March 1, 2027 and 1/16th of the RSUs will vest each June 1, September 1, December 1, and March 1 thereafter, subject to the Reporting Person continuing as a service provider through each such date.
F2 1/4th of the shares subject to the option will vest on February 12, 2027 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.